Literature DB >> 16966832

Symptomatic treatment of multiple sclerosis. Multiple Sclerosis Therapy Consensus Group (MSTCG) of the German Multiple Sclerosis Society.

T Henze1, P Rieckmann, K V Toyka.   

Abstract

Besides immunomodulation and immunosuppression, the specific treatment of symptoms is an essential component of the overall management of multiple sclerosis (MS). Symptomatic treatment is aimed at the elimination or reduction of symptoms impairing the functional abilities and quality of life of the affected patients. Moreover, with symptomatic treatment the development of a secondary physical impairment due to an existing one may be avoided. Many therapeutic techniques as well as different drugs are used for the treatment of MS symptoms, but only a few of them have been investigated, especially in MS patients, and are approved by the national health authorities. Despite an overwhelming number of publications, only a few evidence-based studies exist and consensus reports are very rare, too. Therefore, it seemed necessary to develop a consensus statement on symptomatic treatment of MS comprising existing evidence-based literature as well as therapeutic experience of neurologists who have dealt with these problems over a long time. This consensus paper contains proposals for the treatment of the most common MS symptoms: disorders of motor function and coordination, of cranial nerve function, of autonomic, cognitive, and psychological functions as well as MS-related pain syndromes and epileptic seizures. Copyright 2006 S. Karger AG, Basel.

Entities:  

Mesh:

Year:  2006        PMID: 16966832     DOI: 10.1159/000095699

Source DB:  PubMed          Journal:  Eur Neurol        ISSN: 0014-3022            Impact factor:   1.710


  36 in total

1.  Psychopathology in multiple sclerosis: diagnosis, prevalence and treatment.

Authors:  Ida S Haussleiter; Martin Brüne; Georg Juckel
Journal:  Ther Adv Neurol Disord       Date:  2009-01       Impact factor: 6.570

2.  Basic and escalating immunomodulatory treatments in multiple sclerosis: current therapeutic recommendations.

Authors:  H Wiendl; K V Toyka; P Rieckmann; R Gold; H-P Hartung; R Hohlfeld
Journal:  J Neurol       Date:  2008-10-29       Impact factor: 4.849

3.  Amantadine: multiple sclerosis-related fatigue.

Authors:  Joyce A Generali; Dennis J Cada
Journal:  Hosp Pharm       Date:  2014-09

4.  Use of Accelerometers to Measure Real-Life Physical Activity in Ambulatory Individuals with Multiple Sclerosis: A Pilot Study.

Authors:  Cecilie Fjeldstad; Anette S Fjeldstad; Gabriel Pardo
Journal:  Int J MS Care       Date:  2015 Sep-Oct

Review 5.  [4-Aminopyridine (Fampridine). A new attempt for the symptomatic treatment of multiple sclerosis].

Authors:  L Husseini; V I Leussink; B C Kieseier; H-P Hartung
Journal:  Nervenarzt       Date:  2010-02       Impact factor: 1.214

6.  Emerging evidence-based physical rehabilitation for multiple sclerosis - towards an inventory of current content across Europe.

Authors:  Kamila Rasova; Peter Feys; Thomas Henze; Hans van Tongeren; Davide Cattaneo; Johanna Jonsdottir; Alena Herbenova
Journal:  Health Qual Life Outcomes       Date:  2010-07-28       Impact factor: 3.186

7.  Burden of disease in multiple sclerosis patients with spasticity in Germany: mobility improvement study (Move I).

Authors:  Uwe K Zettl; Thomas Henze; Ute Essner; Peter Flachenecker
Journal:  Eur J Health Econ       Date:  2013-12-01

8.  Utilization of physical rehabilitation among people with multiple sclerosis.

Authors:  I Milivojević; I Adamec; M Habek
Journal:  Ir J Med Sci       Date:  2013-01-22       Impact factor: 1.568

9.  [Importance and treatment of spasticity in multiple sclerosis : results of the MOVE 1 study].

Authors:  T Henze; P Flachenecker; U K Zettl
Journal:  Nervenarzt       Date:  2013-02       Impact factor: 1.214

10.  Multiple sclerosis registry in Germany: results of the extension phase 2005/2006.

Authors:  Peter Flachenecker; Kristin Stuke; Wolfgang Elias; Matthias Freidel; Judith Haas; Dorothea Pitschnau-Michel; Sebastian Schimrigk; Uwe K Zettl; Peter Rieckmann
Journal:  Dtsch Arztebl Int       Date:  2008-02-15       Impact factor: 5.594

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.